Supreme Court Allows Mail-Order of Abortion Pill Mifepristone
Supreme Court allows mail orders of the abortion drug mifepristone pending the outcome of an appeal challenging that method of distributing the medication.
Objective Facts
On Thursday May 14, the Supreme Court allowed mail orders of the abortion drug mifepristone pending the outcome of an appeal. Louisiana, which bans abortion in nearly all cases, sued the FDA over its 2023 decision to lift the in-person requirement, and the 5th Circuit Court of Appeals issued a nationwide ban on mail orders on May 1. Two conservative justices, Clarence Thomas and Samuel Alito, issued written dissents to the Supreme Court's order. The court did not agree to immediately hear the underlying legal arguments, instead sending it back to the 5th Circuit, but the case will likely end up at the Supreme Court again soon.
Left-Leaning Perspective
Pro-choice outlets and advocates framed Thursday's decision as a minimal victory that preserves the status quo but leaves access fundamentally uncertain. Planned Parenthood Action Fund president Alexis McGill Johnson stated the Supreme Court "just did the bare minimum, but this ruling is a relief for patients who can continue to get the care they need," while cautioning this is "just one in a long line of attacks on our rights and our care." Julia Kaye from the ACLU's Reproductive Freedom Project remarked "while it is good news that patients can continue to get this safe medication by mail and at pharmacies as they have for more than five years," the Trump administration "refused to defend the FDA's action and threw patients under the bus" despite being the government defendant in the case. Reproductive Freedom for All president Mini Timmaraju called the case baseless, stating "Mifepristone is safe, effective, and backed by decades of evidence, but anti-abortion extremists dragged this baseless case through the courts," yet acknowledged that "Today's decision gives us temporary relief." Left-leaning coverage emphasized the threat posed by the Trump administration's failure to defend FDA authority and the Comstock Act argument developed by the dissenters. The ACLU characterized the ongoing Trump administration FDA review as "a sham FDA review that is itself a thinly veiled attempt to lay the groundwork for additional medically unjustified restrictions on mifepristone." The Intercept noted concerns that both courts and the Trump administration "could be waiting to make a move on abortion access until after the midterms," and that conservatives "have been eager to use" the Comstock Act "to push a national abortion ban." Democrats argued that "science shows mifepristone is safe for use, decrying Louisiana for urging the Supreme Court to ban the pill in an effort to prevent medical providers from subverting the state's abortion ban." Left-leaning coverage downplayed the majority's reasoning for the stay and emphasized the danger posed by Justices Thomas and Alito's dissents signaling future restrictions. PBS NewsHour constitutional law professor Mary Ziegler noted that Justice Alito's frustration with shield laws protecting providers is important because those state-level clashes could reach SCOTUS, and that Justice Thomas calling drug manufacturers a "criminal enterprise" could have "ramifications for abortion access beyond just mifepristone."
Right-Leaning Perspective
Anti-abortion outlets and officials framed the decision as a setback that undermines state sovereignty and judicial authority, with strong emphasis on the dissenters' legal theories as the path forward. Louisiana Attorney General Liz Murrill, a Republican, called the court's decision "shocking" and stated "the Supreme Court would block this common-sense return to medically ethical practices and oversight," pledging to "keep fighting." Erin Hawley, attorney for the Alliance Defending Freedom litigating alongside Louisiana, criticized the "Biden FDA" for harm caused by its "high-risk drug" and expressed readiness to "litigating our appeal at the 5th Circuit to protect mothers and their children." Gavin Oxley, spokesperson for Americans United for Life, stated that "Mail-order abortion directly undermines the decision in Dobbs," and the ruling would "only further prolong the full effects of overturning Roe v. Wade by incompletely returning the issue to the American people." Conservative dissents from the bench itself provided the intellectual framework for continued attacks. Justice Clarence Thomas wrote in his dissent that "it is a criminal offense to ship mifepristone for use in abortions" under the Comstock Act, and that the drug manufacturers "are not entitled to a stay of an adverse court order based on lost profits from their criminal enterprise." Justice Samuel Alito's separate dissent argued the expanded access to mifepristone "undermines" the Dobbs decision and that manufacturers "have not shown irreparable harm to their businesses," suggesting the FDA could reimpose restrictions at will. The Intercept reported that both justices "railed against the decision," with Alito calling it "a scheme" to get around Dobbs and lamenting that "Abortions have increased since their decision, largely due to telehealth access." Right-leaning coverage underplayed the majority's concerns and framed the dissents as harbingers of future victories, while also criticizing the Trump administration's reluctance to take a clear position. According to CNN, Susan B. Anthony Pro-Life America communications director Kelsey Pritchard said "What is shocking is that the Trump administration's inaction has stopped pro-life laws from taking effect," and complained "It's just really hard for us to understand how the Trump administration has been so negligent as to leave this policy in place."
Deep Dive
The May 14 Supreme Court decision represents the latest chapter in an accelerating conflict over mifepristone access that has fundamentally reshaped how post-Dobbs abortion restrictions play out. After conservative states responded to the 2022 Dobbs decision by banning in-clinic abortions, demand for mifepristone increased significantly, with medication abortions accounting for more than 60% of abortions nationally, and the Society of Family Planning estimating roughly 1 in 4 abortions nationwide were provided through telehealth in 2025, up from fewer than 1 in 10 in 2022. The Biden administration's 2023 decision to formalize COVID-era telehealth access rules created a direct conflict with state abortion bans that Louisiana decided to litigate. A federal district court in April partly sided with Louisiana, finding the FDA's policy was arbitrary and capricious, but held its own decision to give FDA time to complete a review, while the 5th Circuit panel of three judges all appointed by Republicans put the FDA's rule on hold immediately. What each side gets right and omits is instructive. Anti-abortion advocates correctly identify that mail-order mifepristone enables abortion access despite state bans and represents a direct conflict between state sovereignty and federal regulatory authority—a tension the 2024 Supreme Court case attempted to resolve on technical standing grounds but left unresolved on the merits. The Supreme Court's 2024 rejection of anti-abortion groups' challenge solely on standing grounds meant that future challenges were nearly guaranteed. Pro-choice advocates accurately emphasize that every major medical authority endorses mail-order access and that the drug has an excellent safety record, but they minimize the genuine federalism question: why should an abortion-banning state be bound by federal rules enabling what it considers unlawful conduct within its borders? The Trump administration's silence speaks volumes—it appears to be avoiding a forced choice between defending the FDA's scientific judgment (which could alienate its anti-abortion base) and conceding that mail-order mifepristone violates federal law (which could alienate general election voters). Trump's appointees to lead federal health agencies have not shown interest in implementing regulatory changes that would limit access to medication abortion. What comes next will likely determine the contours of abortion access for the next decade. The court did not agree to immediately hear the underlying legal arguments, instead sending it back to the 5th Circuit, but the case will likely end up at the Supreme Court again soon. There is growing concern among abortion-rights advocates that both the courts and the Trump administration could be waiting to restrict access until after the midterms, and that conservatives have been eager to use the Comstock Act theory to push a national abortion ban. The Comstock Act argument, essentially dormant for 150 years, could have implications far beyond mifepristone if adopted by the Court—it potentially threatens the entire supply chain for medication abortion care. Separately, other pending lawsuits by five Republican-led states are aiming to curb access even more drastically, with Texas and Florida having filed a lawsuit targeting the FDA's initial approval of mifepristone in 2000 and subsequent approvals, while Missouri, Kansas and Idaho argue the FDA acted improperly when it eased restrictions in 2016.